Wir verwenden Cookies und Analyse-Tools, um die Nutzerfreundlichkeit der Internet-Seite zu verbessern und für Marketingzwecke. Wenn Sie fortfahren, diese Seite zu verwenden, nehmen wir an, dass Sie damit einverstanden sind. Zur Datenschutzerklärung.
Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease: Volume 15-3
Details
Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.
Zusammenfassung
Hepatitis C Virus is a quickly evolving area within hepatology owing to various medical therapies. This title includes review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors.
Weitere Informationen
- Allgemeine Informationen
- GTIN 09781455711079
- Sprache Englisch
- Genre Medical Books
- Größe H229mm x B152mm
- Jahr 2011
- EAN 9781455711079
- Format Fester Einband
- ISBN 978-1-4557-1107-9
- Veröffentlichung 22.12.2011
- Titel Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease: Volume 15-3
- Autor Poordad Fred
- Gewicht 460g
- Herausgeber SAUNDERS W B CO
- Anzahl Seiten 1